Alternative therapies in staphylococcus aureus diseases

Acta Biochimica Polonica

Volumn 59, Issue 2, 2012, Pages 171-184

  Kurlenda, Julianna ^a   Grinholc, Mariusz ^b  

^a Provincial Hospital   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Alternative therapies; Staphylococcus aureus diseases

Indexed keywords

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 84867160074     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2012_2136     Document Type: Review

References (194)

1. Abele-Horn M, Schupfner B, Emmerling P, Waldner H, Goring H (2000) Persistent wound infection after herniotomy associated with small-colony variants of Staphylococcus aureus. Infection 28: 53-54.
2. Adesokan A, Akanji MA, Yakubu MT (2007) Antibacterial potentials of aqueous extracts of Enatia chlorantha stem bark. Afr J Biotech 6: 2502-2505.
3. Appelbaum PC, Jacobs MR (2005) Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol 8: 510-517.
4. Bahna P, Dvorak T, Hanna H, Yasko AW, Hachem R, Raad I (2007) Orthopaedic metal devices coated with a novel antiseptic dye for the prevention of bacterial infections. Int J Antimicrob Agents 29: 593-596.
5. Balaban N, Cirioni O, Giacometti A, Ghiselli R, Braunstein JB, Silvestri C, Mocchegiani F, Saba V, Scalise G (2007) Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother 51: 2226-2229.
6. Balaban N, Collins LV, Cullor JS, Hume EB, Medina-Acosta E, Vieira da MO, O'Callaghan R, Rossitto PV, Shirtliff ME, Serafim da SL, Tarkowski A, Torres JV (2000) Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides 21: 1301-1311.
7. Balaban N, Goldkorn T, Gov Y, Hirshberg M, Koyfman N, Matthews HR, Nhan RT, Singh B, Uziel O (2001) Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating Protein (TRAP). J Biol Chem 276: 2658-2667.
8. Balaban N, Goldkorn T, Nhan RT, Dang LB, Scott S, Ridgley RM, Rasooly A, Wright SC, Larrick JW, Rasooly R, Carlson JR (1998) Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science 280: 438-440.
9. Balaban N, Gov Y, Bitler A, Boelaert JR (2003) Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells. Kidney Int 63: 340-345.
10. Benfield T, Espersen F, Frimodt-Moller N, Jensen AG, Larsen AR, Pallesen LV, Skov R, Westh H, Skinhoj P (2007) Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect 13: 257-263.
11. Benincasa M, Skerlavaj B, Gennaro R, Pellegrini A, Zanetti M (2003) In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs. Peptides 24: 1723-1731.
12. Bexfield A, Nigam Y, Thomas S, Ratcliffe NA (2004) Detection and partial characterisation of two antibacterial factors from the excretions/secretions of the medicinal maggot Lucilia sericata and their activity against methicillin-resistant Staphylococcus aureus (MRSA). Microbes Infect 6: 1297-1304.
13. Bisland SK, Chien C, Wilson BC, Burch S (2006) Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. Photochem Photobiol Sci 5: 31-38.
14. Brady RA, Leid JG, Camper AK, Costerton JW, Shirtliff ME (2006) Identification of Staphylococcus aureus proteins recognized by the antibody- mediated immune response to a biofilm infection. Infect Immun 74: 3415-3426.
15. Brouillette E, Lacasse P, Shkreta L, Belanger J, Grondin G, Diarra MS, Fournier S, Talbot BG (2002) DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. Vaccine 20: 2348-2357.
16. Browatzki M, Borst MM, Katus HA, Kranzhofer R (2006) Purulent pericarditis and pleural empyema due to Staphylococcus aureus septicemia. Int J Cardiol 107: 117-118.
17. Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, Vazquez V, Etienne J, Lina G, Vandenesch F, Bowden MG (2009) The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect 15: 156-164.
18. Brunel JM, Salmi C, Loncle C, Vidal N, Letourneux Y (2005) Squalamine: a polyvalent drug of the future? Curr Cancer Drug Targets 5: 267-272.
19. Bubeck WJ, Schneewind O (2008) Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205: 287-294.
20. Budzynska A, Rozalski M, Karolczak W, Wieckowska-Szakiel M, Sadowska B, Rozalska B (2011) Synthetic 3-arylideneflavanones as inhibitors of the initial stages of biofilm formation by Staphylococcus aureus and Enterococcus faecalis. Z Naturforsch C 66: 104-114.
21. Burkatovskaya M, Castano AP, midova-Rice TN, Tegos GP, Hamblin MR (2008) Effect of chitosan acetate bandage on wound healing in infected and noninfected wounds in mice. Wound Repair Regen 16: 425-431.
22. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D (2007) Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51: 2765-2773.
23. Chaillou LL, Nazareno MA (2009) Chemical variability in propolis from Santiago del Estero, Argentina, related to the arboreal environment as the sources of resins. J Sci Food Agric 89: 978-983.
24. Chang BS, Moon JS, Kang HM, Kim YI, Lee HK, Kim JD, Lee BS, Koo HC, Park YH (2008) Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle. Vaccine 26: 2081-2091.
25. Chesi G, Colli A, Mestres CA, Gambarati G, Boni F, Gherli T (2006) Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus. BMC Infect Dis 6: 124.
26. Cheung AL, Bayer AS, Zhang G, Gresham H, Xiong YQ (2004) Regulation of virulence determinants in vitro and in vivo in Staphylococcus aureus. FEMS Immunol Med Microbiol 40: 1-9.
27. Chi CY, Wang SM, Lin HC, Liu CC (2006) A clinical and microbiological comparison of Staphylococcus aureus toxic shock and scalded skin syndromes in children. Clin Infect Dis 42: 181-185.
28. Chi W, Qin C, Zeng L, Li W, Wang W (2007) Microbiocidal activity of chitosan-N-2-hydroxypropyl trimethyl ammonium chloride. J Appl Polymer Sci 103: 3851-3856.
29. Chin JN, Rybak MJ, Cheung CM, Savage PB (2007) Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother 51: 1268-1273.
30. Cirioni O, Giacometti A, Ghiselli R, Bergnach C, Orlando F, Mocchegiani F, Silvestri C, Licci A, Skerlavaj B, Zanetti M, Saba V, Scalise G (2006a) Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. Peptides 27: 2104-2110.
31. Cirioni O, Giacometti A, Ghiselli R, Dell'Acqua G, Orlando F, Mocchegiani F, Silvestri C, Licci A, Saba V, Scalise G, Balaban N (2006b) RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. J Infect Dis 193: 180-186.
32. Collins F, Hampton S (2005) Hand-washing and methicillin-resistant Staphylococcus aureus. Br J Nurs 14: 703-707.
33. Collins RJ (2007) Community-acquired methicillin-resistant Staphylococcus aureus in a group home setting. Consult Pharm 22: 763-767.
34. Conceicao T, Ires-de-Sousa M, Fuzi M, Toth A, Paszti J, Ungvari E, van Leeuwen WB, van Belkum A, Grundmann H, de Lencastre H (2007) Replacement of methicillin-resistant Staphylococcus aureus clones in Hungary over time: a 10-year surveillance study. Clin Microbiol Infect 13: 971-979.
35. Cushnie TP, Lamb AJ (2011) Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Agents 38: 99-107.
36. Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O'Callaghan RJ (2002) Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest Ophthalmol Vis Sci 43: 3712-3716.
37. Davis JS (2005) Management of bone and joint infections due to Staphylococcus aureus. Intern Med J 35 (Suppl 2): S79-S96.
38. De KM, Doeschate KT, Dicks LM (2009) Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus. Lett Appl Microbiol 48: 65-70.
39. Del Pozo JL, Alonso M, Arciola CR, Gonzalez R, Leiva J, Lasa I, Penades J (2007) Biotechnological war against biofilms. Could phages mean the end of device-related infections? Int J Artif Organs 30: 805-812.
40. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF (2010) Community- associated meticillin-resistant Staphylococcus aureus. Lancet 375: 1557-1568.
41. Dell'Acqua G, Giacometti A, Cirioni O, Ghiselli R, Saba V, Scalise G, Gov Y, Balaban N (2004) Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. J Infect Dis 190: 318-320.
42. Deresinski S (2006) Antistaphylococcal vaccines and immunoglobulins: current status and future prospects. Drugs 66: 1797-1806.
43. Desachy A, Lina G, Vignon P, Hashemzadeh A, Denis F, Etienne J, Francois B, Ploy MC (2007) Role of superantigenic strains in the prognosis of community-acquired methicillin-susceptible Staphylococcus aureus bacteraemia. Clin Microbiol Infect 13: 1131-1133.
44. Dzwonkowska J, Kurlenda J, Baczkowski B, Mazurkiewicz S, Uzunov I, Ziolkowski W, Markowicz A (2007) The effect of antibiotic therapy on the incidence of Staphylococcus aureus infections in orthopaedic patients. Ortop Traumatol Rehabil 9: 532-547.
45. Embleton ML, Nair SP, Heywood W, Menon DC, Cookson BD, Wilson M (2005) Development of a novel targeting system for lethal photosensitization of antibiotic-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother 49: 3690-3696.
46. Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, Naso R, Horwith G (2004) Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 23: 656-663.
47. Feng Y, Chen CJ, Su LH, Hu S, Yu J, Chiu CH (2008) Evolution and pathogenesis of Staphylococcus aureus: lessons learned from genotyping and comparative genomics. FEMS Microbiol Rev 32: 23-37.
48. Field D, Connor PM, Cotter PD, Hill C, Ross RP (2008) The generation of nisin variants with enhanced activity against specific grampositive pathogens. Mol Microbiol 69: 218-230.
49. Filipowicz N, Kaminski M, Kurlenda J, Asztemborska M, Ochocka JR (2003) Antibacterial and antifungal activity of juniper berry oil and its selected components. Phytother Res 17: 227-231.
50. Finch R (2006) Gram-positive infections: lessons learnt and novel solutions. Clin Microbiol Infect 12: 3-8.
51. Fowler VG, Jr., Justice A, Moore C, Benjamin DK, Jr., Woods CW, Campbell S, Reller LB, Corey GR, Day NP, Peacock SJ (2005a) Risk factors for hematogenous complications of intravascular catheter- associated Staphylococcus aureus bacteremia. Clin Infect Dis 40: 695-703.
52. Fowler VG, Jr., Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS (2005b) Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293: 3012-3021.
53. Fraga CG, Galleano M, Verstraeten SV, Oteiza PI (2010) Basic biochemical mechanisms behind the health benefits of polyphenols. Mol Aspects Med 31: 435-445.
54. Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, Ticehurst JR, Carroll K, Thomas DL, Nuermberger E, Bartlett JG (2005) Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40: 100-107.
55. Gaudreau MC, Lacasse P, Talbot BG (2007) Protective immune responses to a multi-gene DNA vaccine against Staphylococcus aureus. Vaccine 25: 814-824.
56. Ghiselli R, Giacometti A, Cirioni O, Mocchegiani F, Silvestri C, Orlando F, Kamysz W, Licci A, Nadolski P, Della VA, Lukasiak J, Scalise G, Saba V (2007) Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. JPEN J Parenter Enteral Nutr 31: 463-468.
57. Giacometti A, Cirioni O, Barchiesi F, Scalise G (2000) In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics. Diagn Microbiol Infect Dis 38: 115-118.
58. Giacometti A, Cirioni O, Ghiselli R, Bergnach C, Orlando F, D'Amato G, Mocchegiani F, Silvestri C, Del Prete MS, Skerlavaj B, Saba V, Zanetti M, Scalise G (2004) The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Crit Care Med 32: 2485-2490.
59. Giacometti A, Cirioni O, Ghiselli R, Orlando F, Silvestri C, Ranzone G, Testa I, Mocchegiani F, Della VA, Saba V, Scaloni A, Scalise G (2006) Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection. J Biomed Mater Res A 81A: 233-239.
60. Gilbert B, Robbins P, Livornese LL, Jr. (2011) Use of antibacterial agents in renal failure. Med Clin North Am 95: 677-702, vii.
61. Goldstein F (2007) The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 59: 1-4.
62. Gonlugur U, Akkurt I, Ozdemir L, Bakici MZ, Icagasioglu S, Gultekin F (2003) Antibiotic susceptibility patterns of respiratory isolates of Staphylococcus aureus in a Turkish university hospital. Acta Microbiol Pol 52: 143-148.
63. Gorski A, Targonska M, Borysowski J, Weber-Dabrowska B (2009) The potential of phage therapy in bacterial infections of the eye. Ophthalmologica 223: 162-165.
64. Gottlieb GS, Fowler VG, Jr., Kong LK, McClelland RS, Gopal AK, Marr KA, Li J, Sexton DJ, Glower D, Corey GR (2000) Staphylococcus aureus bacteremia in the surgical patient: a prospective analysis of 73 postoperative patients who developed Staphylococcus aureus bacteremia at a tertiary care facility. J Am Coll Surg 190: 50-57.
65. Gravet A, Couppie P, Meunier O, Clyti E, Moreau B, Pradinaud R, Monteil H, Prevost G (2001) Staphylococcus aureus isolated in cases of impetigo produces both epidermolysin A or B and LukE-LukD in 78% of 131 retrospective and prospective cases. J Clin Microbiol 39: 4349-4356.
66. Grinholc M, Kawiak A, Kurlenda J, Graczyk A, Bielawski KP (2008a) Photodynamic effect of protoporphyrin diarginate (PPArg2) on methicillin- resistant Staphylococcus aureus and human dermal fibroblasts. Acta Biochim Pol 55: 85-90.
67. Grinholc M, Szramka B, Kurlenda J, Graczyk A, Bielawski KP (2008b) Bactericidal effect of photodynamic inactivation against methicillinresistant and methicillin-susceptible Staphylococcus aureus is strain-dependent. J Photochem Photobiol B 90: 57-63.
68. Grinholc M, Szramka B, Olender K, Graczyk A (2007a) Bactericidal effect of photodynamic therapy against methicillin-resistant Staphylococcus aureus strain with the use of various porphyrin photosensitizers. Acta Biochim Pol 54: 665-670.
69. Grinholc M, Wegrzyn G, Kurlenda J (2007b) Evaluation of biofilm production and prevalence of the icaD gene in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains isolated from patients with nosocomial infections and carriers. FEMS Immunol Med Microbiol 50: 375-379.
70. Hamblin MR, Hasan T (2004) Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 3: 436-450.
71. Hamblin MR, O'Donnell DA, Murthy N, Rajagopalan K, Michaud N, Sherwood ME, Hasan T (2002) Polycationic photosensitizer conjugates: effects of chain length and Gram classification on the photodynamic inactivation of bacteria. J Antimicrob Chemother 49: 941-951.
72. Harraghy N, Kerdudou S, Herrmann M (2007) Quorum-sensing systems in staphylococci as therapeutic targets. Anal Bioanal Chem 387: 437-444.
73. Healy CM, Palazzi DL, Edwards MS, Campbell JR, Baker CJ (2004) Features of invasive staphylococcal disease in neonates. Pediatrics 114: 953-961.
74. Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM (2004) Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr Pharm Des 10: 2891-2905.
75. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40: 135-136.
76. Hong H, Landauer MR, Foriska MA, Ledney GD (2006) Antibacterial activity of the soy isoflavone genistein. J Basic Microbiol 46: 329-335.
77. Hu DL, Omoe K, Narita K, Cui JC, Shinagawa K, Nakane A (2006) Intranasal vaccination with a double mutant of staphylococcal enterotoxin C provides protection against Staphylococcus aureus infection. Microbes Infect 8: 2841-2848.
78. Huang YH, Tseng SP, Hu JM, Tsai JC, Hsueh PR, Teng LJ (2007) Clonal spread of SCCmec type IV methicillin-resistant Staphylococcus aureus between community and hospital. Clin Microbiol Infect 13: 717-724.
79. Hudson MC, Ramp WK, Frankenburg KP (1999) Staphylococcus aureus adhesion to bone matrix and bone-associated biomaterials. FEMS Microbiol Lett 173: 279-284.
80. Ito T, Hiramatsu K (2003) [MRSA (methicillin-resistant Staphylococcus aureus)]. Nippon Rinsho 61 (Suppl 3): 164-170.
81. Ito T, Katayama Y, Asada K, Mori N, Tsutsumimoto K, Tiensasitorn C, Hiramatsu K (2001) Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45: 1323-1336.
82. James PR (2001) Isolated pericardial empyema secondary to Staphylococcus aureus. Eur J Intern Med 12: 377-379.
83. Janiszewska J, Urbanczyk-Lipkowska Z (2006) Synthesis, antimicrobial activity and structural studies of low molecular mass lysine dendrimers. Acta Biochim Pol 53: 77-82.
84. Jarraud S, Mougel C, Thioulouse J, Lina G, Meugnier H, Forey F, Nesme X, Etienne J, Vandenesch F (2002) Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun 70: 631-641.
85. Jin T, Bokarewa M, Tarkowski A (2005) Urokinase-type plasminogen activator, an endogenous antibiotic. J Infect Dis 192: 429-437.
86. Jori G, Brown SB (2004) Photosensitized inactivation of microorganisms. Photochem Photobiol Sci 3: 403-405.
87. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T (2001) Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184: 1572-1580.
88. Kaiser AM, Schultsz C, Kruithof GJ, Bets-Ossenkopp Y, Vandenbroucke-Grauls C (2004) Carriage of resistant microorganisms in repatriates from foreign hospitals to The Netherlands. Clin Microbiol Infect 10: 972-979.
89. Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, de Baere GA (2000) Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect Control Hosp Epidemiol 21: 319-323.
90. Kampf G, Meyer B, Goroncy-Bermes P (2003) Comparison of two test methods for the determination of sufficient antimicrobial activity of three commonly used alcohol-based hand rubs for hygienic hand disinfection. J Hosp Infect 55: 220-225.
91. Karchmer AW (2006) From theory to practice: resistance in Staphylococcus aureus and new treatments. Clin Microbiol Infect 12: 15-21.
92. Keilman VK (1979) Prevention of purulent complications in the combined treatment of open fractures of crus bones. Sov Med 52-55.
93. Kerro-Dego O, Prysliak T, Potter AA, Perez-Casal J (2006) DNAprotein immunization against the GapB and GapC proteins of a mastitis isolate of Staphylococcus aureus. Vet Immunol Immunopathol 113: 125-138.
94. Kilani-Jaziri S, Frachet V, Bhouri W, Ghedira K, Chekir-Ghedira L, Ronot X (2011) Flavones inhibit the proliferation of human tumor cancer cell lines by inducing apoptosis. Drug Chem Toxicol 35: 1-10.
95. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ (2003) Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47: 1589-1597.
96. Komerik N, Nakanishi H, MacRobert AJ, Henderson B, Speight P, Wilson M (2003) In vivo killing of Porphyromonas gingivalis by toluidine blue-mediated photosensitization in an animal model. Antimicrob Agents Chemother 47: 932-940.
97. Korem M, Sheoran AS, Gov Y, Tzipori S, Borovok I, Balaban N (2003) Characterization of RAP, a quorum sensing activator of Staphylococcus aureus. FEMS Microbiol Lett 223: 167-175.
98. Kowalski TJ, Berbari EF, Osmon DR (2005) Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin Proc 80: 1201-1207.
99. Kristiansen MM, Leandro C, Ordway D, Martins M, Viveiros M, Pacheco T, Molnar J, Kristiansen JE, Amaral L (2006) Thioridazine reduces resistance of methicillin-resistant Staphylococcus aureus by inhibiting a reserpine-sensitive efflux pump. In Vivo 20: 361-366.
100. Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, Ljungh A (2004) Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother 54: 648-653.
101. Kuint J, Barzilai A, Regev-Yochay G, Rubinstein E, Keller N, Maayan-Metzger A (2007) Comparison of community-acquired methicillinresistant Staphylococcus aureus bacteremia to other staphylococcal species in a neonatal intensive care unit. Eur J Pediatr 166: 319-325.
102. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, Noble L, Brown MJ, Zorman JK, Wang XM, Pancari G, Fan H, Isett K, Burgess B, Bryan J, Brownlow M, George H, Meinz M, Liddell ME, Kelly R, Schultz L, Montgomery D, Onishi J, Losada M, Martin M, Ebert T, Tan CY, Schofield TL, Nagy E, Meineke A, Joyce JG, Kurtz MB, Caulfield MJ, Jansen KU, McClements W, Anderson AS (2006) A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 74: 2215-2223.
103. Kurlenda J, Grinholc M, Jasek K, Wegrzyn G (2007) RAPD typing of methicillin-resistant Staphylococcus aureus: a 7-year experience in a Polish hospital. Med Sci Monit 13: MT13-MT18.
104. Kurlenda J, Grinholc M, Krzyszton-Russjan J, Wisniewska K (2009) Epidemiological investigation of nosocomial outbreak of staphylococcal skin diseases in neonatal ward. Antonie Van Leeuwenhoek [Epub ahead of print].
105. Ladhani S, Garbash M (2005) Staphylococcal skin infections in children:(2009) rational drug therapy recommendations. Paediatr Drugs 7: 77-102.
106. Le T, I, Mariani-Kurkdjian P, Collignon A, Gravet A, Clermont O, Brahimi N, Gaudelus J, Aujard Y, Navarro J, Beaufils F, Bingen E (2001) Breast milk transmission of a Panton-Valentine leukocidinproducing Staphylococcus aureus strain causing infantile pneumonia. J Clin Microbiol 39: 728-729.
107. LeClaire RD, Hunt RE, Bavari S (2002) Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun 70: 2278-2281.
108. Leszczynski P, Weber-Dabrowska B, Kohutnicka M, Luczak M, Gorecki A, Gorski A (2006) Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare workerm - case report. Folia Microbiol (Praha) 51: 236-238.
109. Levy SB (2005) Antibiotic resistance-the problem intensifies. Adv Drug Deliv Rev 57: 1446-1450.
110. Lew DP, Waldvogel FA (2004) Osteomyelitis. Lancet 364: 369-379.
111. Lipovsky A, Nitzan Y, Friedmann H, Lubart R (2009) Sensitivity of Staphylococcus aureus strains to broadband visible light. Photochem Photobiol 85: 255-260.
112. Livermore DM (2006) Can beta-lactams be re-engineered to beat MRSA? Clin Microbiol Infect 12 (Suppl 2): 11-16.
113. Maia GL, Falcao-Silva VS, Aquino PG, de Araujo-Junior JX, Tavares JF, da Silva MS, Rodrigues LC, de Siqueira-Junior JP, Barbosa-Filho JM (2011) Flavonoids from Praxelis clematidea R.M. King and Robinson modulate bacterial drug resistance. Molecules 16: 4828-4835.
114. Maira-Litran T, Kropec A, Goldmann D, Pier GB (2004) Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide. Vaccine 22: 872-879.
115. Maira-Litran T, Kropec A, Goldmann DA, Pier GB (2005) Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly- N-acetyl-beta-(1-6)-glucosamine. Infect Immun 73: 6752-6762.
116. Maisch T, Bosl C, Szeimies RM, Lehn N, Abels C (2005) Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells. Antimicrob Agents Chemother 49: 1542-1552.
117. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A, Imai S (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187: 613-624.
118. McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Doring G, Lee JC, Goldmann DA, Pier GB (1999) Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284: 1523-1527.
119. Menzies BE, Kourteva Y, Kaiser AB, Kernodle DS (2002) Inhibition of staphylococcal wound infection and potentiation of antibiotic prophylaxis by a recombinant fragment of the fibronectin-binding protein of Staphylococcus aureus. J Infect Dis 185: 937-943.
120. Mohr H, Redecker-Klein A (2003) Inactivation of pathogens in platelet concentrates by using a two-step procedure. Vox Sang 84: 96-104.
121. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355: 666-674.
122. Murray RJ (2005) Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern Med J 35 (Suppl 2): S106-S119.
123. Naffa RG, Bdour SM, Migdadi HM, Shehabi AA (2006) Enterotoxicity and genetic variation among clinical Staphylococcus aureus isolates in Jordan. J Med Microbiol 183-187.
124. Narita K, Hu DL, Tsuji T, Nakane A (2008) Intranasal immunization of mutant toxic shock syndrome toxin 1 elicits systemic and mucosal immune response against Staphylococcus aureus infection. FEMS Immunol Med Microbiol 52: 389-396.
125. Nascimento JS, Ceotto H, Nascimento SB, Giambiagi-Demarval M, Santos KR, Bastos MC (2006) Bacteriocins as alternative agents for control of multiresistant staphylococcal strains. Lett Appl Microbiol 42: 215-221.
126. Nema V, Agrawal R, Kamboj DV, Goel AK, Singh L (2007) Isolation and characterization of heat resistant enterotoxigenic Staphylococcus aureus from a food poisoning outbreak in Indian subcontinent. Int J Food Microbiol 117: 29-35.
127. Nowakowska M, Jarosz-Chobot P, Polanska J, Machnica L (2007) Bacterial strains colonizing subcutaneous catheters of personal insulin pumps. Pol J Microbiol 56: 239-243.
128. Oh I, Yang WY, Chung SC, Kim TY, Oh KB, Shin J (2011) In vitro sortase A inhibitory and antimicrobial activity of flavonoids isolated from the roots of Sophora flavescens. Arch Pharm Res 34: 217-222.
129. Oh S, Kim SH, Ko Y, Sim JH, Kim KS, Lee SH, Park S, Kim YJ (2006) Effect of bacteriocin produced by Lactococcus sp. HY 449 on skin-inflammatory bacteria. Food Chem Toxicol 44: 1184-1190.
130. Omoe K, Ishikawa M, Shimoda Y, Hu DL, Ueda S, Shinagawa K (2002) Detection of seg, seh, and sei genes in Staphylococcus aureus isolates and determination of the enterotoxin productivities of S. aureus isolates Harboring seg, seh, or sei genes. J Clin Microbiol 40: 857-862.
131. Onlen Y, Duran N, Atik E, Savas L, Altug E, Yakan S, Aslantas O (2007) Antibacterial activity of propolis against MRSA and synergism with topical mupirocin. J Altern Complement Med 13: 713-718.
132. Otto M (2008) Targeted immunotherapy for staphylococcal infections: focus on anti-MSCRAMM antibodies. Bio Drugs 22: 27-36.
133. Ozcelik B, Kartal M, Orhan I (2011) Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids. Pharm Biol 49: 396-402.
134. Parfitt T (2005) Georgia: an unlikely stronghold for bacteriophage therapy. Lancet 365: 2166-2167.
135. Pei L (2004) New approaches to develop anti-staphylococcal agents. Curr Med Chem -Anti Inf Agents 267-278.
136. Peloi LS, Soares RR, Biondo CE, Souza VR, Hioka N, Kimura E (2008) Photodynamic effect of light-emitting diode light on cell growth inhibition induced by methylene blue. J Biosci 33: 231-237.
137. Perez MM, Prenafeta A, Valle J, Penades J, Rota C, Solano C, Marco J, Grillo MJ, Lasa I, Irache JM, Maira-Litran T, Jimenez-Barbero J, Costa L, Pier GB, de Andrés D, Amorena B (2009) Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl beta-1,6 glucosamine specific antibody production using biofilm-embedded bacteria. Vaccine 27: 2379-2386.
138. Peschel A (2002) How do bacteria resist human antimicrobial peptides? Trends Microbiol 10: 179-186.
139. Peschel A, Collins LV (2001) Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin. Peptides 22: 1651-1659.
140. Plata K, Rosato AE, Wegrzyn G (2009) Staphylococcus aureus as an infectious agent: overview of biochemistry and molecular genetics of its pathogenicity. Acta Biochim Pol 56: 597-612.
141. Priest DH, Peacock JE, Jr. (2005) Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes. South Med J 98: 854-862.
142. Rayner C, Munckhof WJ (2005) Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Intern Med J 35 (Suppl 2): S3-16.
143. Regev-Yochay G, Rubinstein E, Barzilai A, Carmeli Y, Kuint J, Etienne J, Blech M, Smollen G, Maayan-Metzger A, Leavitt A, Rahav G, Keller N (2005) Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Emerg Infect Dis 11: 453-456.
144. Rennermalm A, Li YH, Bohaufs L, Jarstrand C, Brauner A, Brennan FR, Flock JI (2001) Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 19: 3376-3383.
145. Richards RG, Harris LG, Schneider E, Haas N (2006) Antiseptics and antibiotics on implants. Int J Care Injured 37: 113-116.
146. Roberts S, Chambers S (2005) Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. Intern Med J 35 (Suppl 2): S97-105.
147. Romanov VP, Lebedev LR, Tereshchenko TA, Nazarikova NI, Masycheva VI (2001) [Photoinactivation of microorganisms in the presence of photosensitizers]. Zh Mikrobiol Epidemiol Immunobiol 24-26.
148. Romanova NA, Brovko LY, Moore L, Pometun E, Savitsky AP, Ugarova NN, Griffiths MW (2003) Assessment of photodynamic destruction of Escherichia coli O157:H7 and Listeria monocytogenes by using ATP bioluminescence. Appl Environ Microbiol 69: 6393-6398.
149. Runarsson O, Holappa J, Nevalainen T, Hjalmarsdottir M, Jarvinen T, Loftsson T, Einarsson JM, Jonsdottir S, Valdimarsdottir M, Masson M (2007) Antibacterial activity of methylated chitosan and chitooligomer derivatives: synthesis and structure activity relationships. Eur Polymer J 43: 2660-2671.
150. Sadowska B, Cochard T, Poutrel B, Pytlos M, Bonar A, Gatkowska J, Rudnicka W, Polak J, Bielecki S, Siwinska-Gol bH, Rozalska B (2001) Characterization of Staphylococcus aureus strains isolated from cystic fibrosis patients by conventional and molecular typing. Acta Microbiol Pol 50: 251-261.
151. Salmi C, Loncle C, Vidal N, Laget M, Letourneux Y, Brunel JM (2008a) New 3-aminosteroid derivatives as a new family of topical antibacterial agents active against methicillin-resistant Staphylococcus aureus (MRSA). Lett Drug Design Disc 5: 169-172.
152. Salmi C, Loncle C, Vidal N, Letourneux Y, Brunel JM (2008b) New stereoselective titanium reductive amination synthesis of 3-amino and polyaminosterol derivatives possessing antimicrobial activities. Eur J Med Chem 43: 540-547.
153. Sandhu K, Kanwar AJ (2004) Generalized bullous impetigo in a neonate. Pediatr Dermatol 21: 667-669.
154. Sandrini MP, Shannon O, Clausen AR, Bjorck L, Piskur J (2007) Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria. Antimicrob Agents Chemother 51: 2726-2732.
155. Savas L, Duran N, Onlen Y, Savas N, Erayman M (2005) Prospective analysis of antibiotic susceptibility patterns of MRSA in a Turkish University Hospital. Turk J Med Sci 35: 323-327.
156. Schaffer AC, Lee JC (2008) Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents 32 (Suppl 1): S71-S78.
157. Seifert H, Wisplinghoff H, Schnabel P, von Eiff C (2003) Small colony variants of Staphylococcus aureus and pacemaker-related infection. Emerg Infect Dis 9: 1316-1318.
158. Senna JP, Roth DM, Oliveira JS, Machado DC, Santos DS (2003) Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach. Vaccine 21: 2661-2666.
159. Severina E, Severin A, Tomasz A (1998) Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. J Antimicrob Chemother 41: 341-347.
160. Sforcin JM, Bankova V (2011) Propolis: is there a potential for the development of new drugs? J Ethnopharmacol 133: 253-260.
161. Shannon O, Uekotter A, Flock JI (2006) The neutralizing effects of hyperimmune antibodies against extracellular fibrinogen-binding protein, Efb, from Staphylococcus aureus. Scand J Immunol 63: 184-190.
162. Sharma M, Visai L, Bragheri F, Cristiani I, Gupta PK, Speziale P (2008) Toluidine blue-mediated photodynamic effects on staphylococcal biofilms. Antimicrob Agents Chemother 52: 299-305.
163. Shinefield HR (2006) Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible? Vaccine 24 Suppl 2: S2-S9.
164. Simonetti O, Cirioni O, Ghiselli R, Goteri G, Scalise A, Orlando F, Silvestri C, Riva A, Saba V, Madanahally KD, Offidani A, Balaban N, Scalise G, Giacometti A (2008) RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 52: 2205-2211.
165. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A (1987) Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz) 35: 569-583.
166. Smeltzer MS, Gillaspy AF (2000) Molecular pathogenesis of staphylcoccal osteomyelitis. Poult Sci 79: 1042-1049.
167. Sola C, Gribaudo G, Vindel A, Patrito L, Bocco JL (2002) Identification of a novel methicillin-resistant Staphylococcus aureus epidemic clone in Cordoba, Argentina, involved in nosocomial infections. J Clin Microbiol 40: 1427-1435.
168. Soncin M, Fabris C, Busetti A, Dei D, Nistri D, Roncucci G, Jori G (2002) Approaches to selectivity in the Zn(II)-phthalocyanine-photosensitized inactivation of wild-type and antibiotic-resistant Staphylococcus aureus. Photochem Photobiol Sci 1: 815-819.
169. Soukos NS, Ximenez-Fyvie LA, Hamblin MR, Socransky SS, Hasan T (1998) Targeted antimicrobial photochemotherapy. Antimicrob Agents Chemother 42: 2595-2601.
170. Spanu T, Romano L, D'Inzeo T, Masucci L, Albanese A, Papacci F, Marchese E, Sanguinetti M, Fadda G (2005) Recurrent ventriculoperitoneal shunt infection caused by small-colony variants of Staphylococcus aureus. Clin Infect Dis 41: e48-e52.
171. Stranger-Jones YK, Bae T, Schneewind O (2006) Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103: 16942-16947.
172. Stryjewski ME, Hall RP, Chu VH, Kanafani ZA, O'Riordan WD, Weinstock MS, Stienecker RS, Streilein R, Dorschner RA, Fowler VG, Jr., Corey GR, Gallo RL (2007) Expression of antimicrobial peptides in the normal and involved skin of patients with infective cellulitis. J Infect Dis 196: 1425-1430.
173. Sulakvelidze A, Alavidze Z, Morris JG, Jr. (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45: 649-659.
174. Svetoch EA, Levchuk VP, Pokhilenko VD, Eruslanov BV, Mitsevich EV, Mitsevich IP, Perelygin VV, Stepanshin YG, Stern NJ (2008) Inactivating methicillin-resistant Staphylococcus aureus and other pathogens by use of bacteriocins OR-7 and E 50-52. J Clin Microbiol 46: 3863-3865.
175. Tacconelli E (2006) New strategies to identify patients harbouring antibiotic- resistant bacteria at hospital admission. Clin Microbiol Infect 12: 102-109.
176. Tajima Y (2005) Polyoxotungstates reduce the beta-lactam resistance of methicillin-resistant Staphylococcus aureus. Mini Rev Med Chem 5: 255-268.
177. Thanacoody HK (2007) Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmacol 64: 566-574.
178. Therrien R, Lacasse P, Grondin G, Talbot BG (2007) Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagenbinding protein. Vaccine 25: 5053-5061.
179. Trampuz A, Zimmerli W (2006) Antimicrobial agents in orthopaedic surgery: Prophylaxis and treatment. Drugs 66: 1089-1105.
180. Vayalumkal JV, Jadavji T (2006) Children hospitalized with skin and soft tissue infections: a guide to antibacterial selection and treatment. Paediatr Drugs 8: 99-111.
181. Verbeken G, De VD, Vaneechoutte M, Merabishvili M, Zizi M, Pirnay JP (2007) European regulatory conundrum of phage therapy. Future Microbiol 2: 485-491.
182. Verdrengh M, Collins LV, Bergin P, Tarkowski A (2004) Phytoestrogen genistein as an anti-staphylococcal agent. Microbes Infect 6: 86-92.
183. Wang Q, Wang H, Xie M (2010) Antibacterial mechanism of soybean isoflavone on Staphylococcus aureus. Arch Microbiol 192: 893-898.
184. Whyte D, Monahan R, Boyle L, Slevin B, FitzGerald R, Barron D, De FJ, Kelleher K (2005) The incidence of S. aureus bacteraemia in acute hospitals of the Mid-Western Area, Ireland, 2002-2004. Euro Surveill 10: 75-77.
185. Wills QF, Kerrigan C, Soothill JS (2005) Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 49: 1220-1221.
186. Wilson M (2004) Lethal photosensitisation of oral bacteria and its potential application in the photodynamic therapy of oral infections. Photochem Photobiol Sci 3: 412-418.
187. Witte W, Pasemann B, Cuny C (2007) Detection of low-level oxacillin resistance in mecA-positive Staphylococcus aureus. Clin Microbiol Infect 13: 408-412.
188. Yacoby I, Bar H, Benhar I (2007) Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob Agents Chemother 51: 2156-2163.
189. Yang XP, Li EW, Zhang Q, Yuan CS, Jia ZJ (2006) Five new iridoids from Patrinia rupestris. Chem Biodivers 3: 762-770.
190. Yin S, Fan CQ, Wang Y, Dong L, Yue JM (2004) Antibacterial prenylflavone derivatives from Psoralea corylifolia, and their structureactivity relationship study. Bioorg Med Chem 12: 4387-4392.
191. Zanetti M, Gennaro R, Skerlavaj B, Tomasinsig L, Circo R (2002) Cathelicidin peptides as candidates for a novel class of antimicrobials. Curr Pharm Des 8: 779-793.
192. Zeina B, Greenman J, Corry D, Purcell WM (2002) Cytotoxic effects of antimicrobial photodynamic therapy on keratinocytes in vitro. Br J Dermatol 146: 568-573.
193. Zeina B, Greenman J, Corry D, Purcell WM (2003) Antimicrobial photodynamic therapy: assessment of genotoxic effects on keratinocytes in vitro. Br J Dermatol 148: 229-232.
194. Zhou H, Xiong ZY, Li HP, Zheng YL, Jiang YQ (2006) An immunogenicity study of a newly fusion protein Cna-FnBP vaccinated against Staphylococcus aureus infections in a mice model. Vaccine 24: 4830-4837.